We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Targeted Therapy for Renal Cell Carcinoma: a Prospective study.
- Authors
Joshi, Robin; Rawal, Sudhir
- Abstract
Introduction: Our study aims to evaluate the use of targeted therapy in metastatic renal cell carcinoma Methods: This is a prospective study done over three years from December 2010 to December, 2013. Out of Forty seven patients of metastatic renal cell carcinoma 8 (neo-adjuvant cases) were excluded and 39 were included in this study. All patients received Tyrosine kinase inhibitor, sunitinib therapy (50 mg OD, 4/2 scheme). All 39 patients underwent radical nephrectomy prior to sunitinib therapy. Patients were followed up every cycle for their clinical symptoms following sunitinib therapy and every 3 months with chest X-ray, ultra-sonography and bone scan. CT scan was done if needed. A RECIST criterion was used to evaluate the complete, partial and no tumor response. Results: The median survival was 28.5 months (CI 9.253-47.7) and progression free survival (PFS) was 9.16 months (CI 6.08-12.23). According to RECIST, stable disease was found in 6 patients till date and a complete response in two patients. Clear cell histology was found in 30 (76.9%) patients, papillary variety in 6 (15.39%) patients, chromophobe type was seen in one patient and rest had mixed sarcomatoid papillary and rhabdoid clear cell variety. Twenty four patients (61.5%) had multiple metastases. Most frequent metastasis was seen in lungs in 14 patients (36%) and bone in 12 patients (31%). Metastases were also seen in draining lymph nodes, adrenals, omentum, skin, liver, and brain. Conclusions: In our cohort, use of sunitinib showed similar outcome to previously published articles. Our study supports the use of sunitinib in metastatic renal cell carcinoma.
- Publication
Journal of the Nepal Medical Association, 2015, Vol 53, Issue 198, p83
- ISSN
0028-2715
- Publication type
Article
- DOI
10.31729/jnma.2767